Evidence map›Paper›PMID 42104448›Full record

ArticleGenome biology2026

LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling.

Zihong Kang, Ruimeng Li, Lei Xu, Yunfan Xiang, Yuhang Qiu, Yue Zhou, Lei Wang, Xuerui Yang, Jun Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zihong Kang *State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.
Ruimeng Li *MOE Key Laboratory of Bioinformatics, Center for Synthetic & Systems Biology, School of Life Sciences, Joint Graduate Program of Peking-Tsinghua-National Institute of Biological Science, Tsinghua University, Beijing, 100084, China.
Lei Xu *Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, 210008, China.
Yunfan XiangState Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.
Yuhang QiuState Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.
Yue ZhouDepartment of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, 210008, China.
Lei WangDepartment of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, 210008, China. leiwang9631@nju.edu.cn.
Xuerui YangMOE Key Laboratory of Bioinformatics, Center for Synthetic & Systems Biology, School of Life Sciences, Joint Graduate Program of Peking-Tsinghua-National Institute of Biological Science, Tsinghua University, Beijing, 100084, China. yangxuerui@tsinghua.edu.cn.
Jun LiuState Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China. junliu1223@pku.edu.cn.

Funding

Beijing Nova Program Z211100002121011 and 20230484442 to J.L.national key research and development program of china 2023YFC3402200 to J.L. and 2023YFC3043300 to X.Y.National Natural Science Foundation of China 32170595 to J.L. and 32330022 and 81972912 to X.Y.
6 · The paper itself

Abstract

backgroundRepression of DNA damage repair by PARP inhibitors (PARPi) has shown great efficacy in cancer treatment. However, therapy resistance remains a significant clinical challenge.

resultsHere, we demonstrate that the N

conclusionsOur findings unveil a novel regulatory mechanism of L1 m

Indexed as

Chromatin Assembly and DisassemblyLong Interspersed Nucleotide ElementsPoly(ADP-ribose) Polymerase InhibitorsAdenosineCell Line, TumorDemethylationDNA DamageDNA RepairDrug Resistance, NeoplasmEpitranscriptomeHumansMethyltransferasesPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1RNA MethylationAdenosineMethyltransferasesMETTL3 protein, humanN-methyladenosineolaparibPARP1 protein, humanPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsH3K9me3 modificationHR repairLINE1 RNA methylationPARPi sensitivity

Identifiers

PMID42104448
PMCPMC13321487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.